Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform study of VIR-3434 and VIR-2218-based combination therapies for chronic hepatitis B
ISRCTN29337285Phase 2Terminated
- Sponsor
- Vir Biotechnology
- Start
- Oct 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tobevibart, elebsiran, pegylated interferon alpha and tenofovir disoproxil fumarate in hepatitis B (HBV), sponsored by Vir Biotechnology. Primary endpoints: Sustained HBV DNA suppression at 24 weeks after treatment discontinuation, Sustained HBV DNA suppression with HBsAg loss at 24 weeks after treatment discontinuation and 5 more. Started Oct 2022; status: terminated.
02
Drugs
tobevibartelebsiranpegylated interferon alphatenofovir disoproxil fumarate
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ISRCTN29337285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29337285.